3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
10
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
4
Neoplasm Metastasis
4
Breast Neoplasms
4
Neoplasms
3
Urethral Neoplasms
2
Recurrence
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Carboplatin
27
Paclitaxel
23
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Pemetrexed
8
Everolimus
8
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Nivolumab
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Irinotecan
4
Gefitinib
4
vosaroxin
3
volociximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
vinflunine
×
Clear all
NCT01529411
2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
86 enrolled